The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: a multicentre, non-randomised, open-label phase 2 study
- Resource Type
- Article
- Authors
- Ramchandren, Radhakrishnan; Johnson, Peter; Ghosh, Nilanjan; Ruan, Jia; Ardeshna, Kirit M.; Johnson, Roderick; Verhoef, Gregor; Cunningham, David; de Vos, Sven; Kassam, Shireen; Fayad, Luis; Radford, John; Bailly, Sarah; Offner, Fritz; Morgan, David; Munoz, Javier; Ping, Jerry; Szafer-Glusman, Edith; Eckert, Karl; Neuenburg, Jutta K.; Goy, Andre
- Source
- In eClinicalMedicine February 2023 56
- Subject
- Language
- ISSN
- 2589-5370